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Introduction
Bladder cancer is a common and worldwide health problem.1 
Most bladder cancers arise from the urothelium (urothelial cell 
carcinomas ‘UCC’), of which 70% to 80% are non-muscle 
invasive bladder cancers (NMIBC) at presentation.2 Grade 3 
NMIBC is a clinically important sub-type of bladder UCC, 
accounting for approximately 10% to 15% of all NMIBCs at 
presentation and considered to be ‘high-risk’ NMIBC 
(HR-NMIBC).3,4 These tumours are more aggressive than 
their low- and intermediate-risk counterparts and manifest by 
higher rates of tumour recurrence, progression to muscle 
invasive bladder cancer (MIBC) and/or metastatic disease 
despite intra-vesical therapies.5,6 Although progression to 
MIBC is associated with poor outcomes, many HR-NMIBC 
tumours do not recur or progress. Therefore, immediate radical 
cystectomy based on estimated future risks may be considered 
‘over-treatment’ with inherent morbidity and quality of life 
implications.3,5,7
As adverse patient outcomes may result from under-treat-
ment with intra-vesical therapies alone, or from over-treatment 
with early radical surgery, additional methods of risk 
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ABSTRACT
BACKgRouND: High-risk non-muscle invasive bladder cancer (HR-NMIBC) is a clinically unpredictable disease. Despite clinical risk esti-
mation tools, many patients are undertreated with intra-vesical therapies alone, whereas others may be over-treated with early radical sur-
gery. Molecular biomarkers, particularly DNA methylation, have been reported as predictive of tumour/patient outcomes in numerous solid 
organ and haematologic malignancies; however, there are few reports in HR-NMIBC and none using genome-wide array assessment. We 
therefore sought to identify novel DNA methylation markers of HR-NMIBC clinical outcomes that might predict tumour behaviour at initial 
diagnosis and help guide patient management.
PATIeNTS AND MeTHoDS: A total of 21 primary initial diagnosis HR-NMIBC tumours were analysed by Illumina HumanMethylation450 
BeadChip arrays and subsequently bisulphite Pyrosequencing. In all, 7 had not recurred at 1 year after resection and 14 had recurred and/
or progressed despite intra-vesical BCG. A further independent cohort of 32 HR-NMIBC tumours (17 no recurrence and 15 recurrence and/
or progression despite BCG) were also assessed by bisulphite Pyrosequencing.
ReSulTS: Array analyses identified 206 CpG loci that segregated non-recurrent HR-NMIBC tumours from clinically more aggressive recur-
rence/progression tumours. Hypermethylation of CpG cg11850659 and hypomethylation of CpG cg01149192 in combination predicted HR-
NMIBC recurrence and/or progression within 1 year of diagnosis with 83% sensitivity, 79% specificity, and 83% positive and 79% negative 
predictive values.
CoNCluSIoNS: This is the first genome-wide DNA methylation analysis of a unique HR-NMIBC tumour cohort encompassing known 
1-year clinical outcomes. Our analyses identified potential novel epigenetic markers that could help guide individual patient management in 
this clinically unpredictable disease.
KeywoRDS: high-risk non-muscle invasive bladder cancer, epigenetics, methylation, HumanMethylation450 BeadChip array, prognostic 
biomarker
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estimation are required. The European Association of Urology 
(EAU) recommends the use of the European Organisation for 
the Research and Treatment of Cancer (EORTC) risk estima-
tion tool.3 This provides 1- to 5-year estimates of disease recur-
rence and progression each year. However, this tool generates 
estimates only and is based on 10-year-old data with recog-
nised limitations.8 Therefore, additional methods of risk strati-
fication to support clinical decision making (for the patient and 
surgeon) are required.9 In this regard, molecular markers are a 
key area of investigation.
As HR-NMIBC tumours appear to be molecularly hetero-
geneous,10 previous investigations have failed to find common 
genetic changes as reliable biomarkers, either as stand-alone 
‘tests’ or in combination with clinical parameters.9,11 However, 
epigenetic modifications, and particularly DNA methylation, 
have been identified as diagnostic and prognostic in numerous 
solid organ and haematologic malignancies, even in those con-
sidered particularly heterogeneous, for example, lung and 
malignant melanoma.12,13 Furthermore, DNA methylation 
changes are ideal for biomarker exploitation as they occur early 
in tumour development and are stable and readily measura-
ble.14 However, although previous reports in HR-NMIBC 
have suggested correlations with clinical outcomes,14,15 few 
studies have sought to assess DNA methylation patterns as 
prognostic in this tumour type, with limitations in number of 
genes assessed, sample heterogeneity, and the presence of other 
bladder tumour types.16–19
To more comprehensively assess DNA methylation for 
biomarker potential in HR-NMIBC, we used Illumina 
HumanMethylation450 BeadChip array technology. Our 
‘450K’ array interrogated a unique cohort of HR-NMIBC 
with 1-year clinical outcomes of ‘no recurrence’, ‘recurrence’, 
or ‘progression’. Through comparisons of DNA methylation 
patterns, we identified epigenetic differences between these 
outcome ‘sub-types’ of HR-NMIBC. We thus report poten-
tial prognostic methylation biomarkers that may guide 
patient management at initial diagnosis of this unpredictable 
disease.
Patients and Methods
Human tissue samples
Primary tumour and normal bladder tissues were provided by 
the Bladder Cancer Prognosis Programme (BCPP, National 
Research Ethics Service East Midlands – Derby 06/
MRE04/65),20 the University of Birmingham Human 
Biomaterials Resource Centre (National Research Ethics 
Service [North West 5]: 09/H1010/75), and the University 
Hospitals of North Midlands NHS Trust (National Research 
Ethics Service [South Central – Oxford C]: 12/SC/0725). All 
samples were confirmed histologically as G3 T1 UCC (dis-
covery cohort n = 21, validation cohort n = 32). All tumours 
were from initial presentation bladder tumours, in patients 
with no prior history of bladder cancer and intra-vesical 
therapies. As previously described,21 patients received repeat 
bladder tumour resection (TURBT [transurethral resection of 
bladder tumour]), intra-vesical therapy, and/or cystectomy as 
recommended by EAU guidelines.22 All samples (Supplemental 
Table S1) were stored at −80°C prior to nucleic acid extrac-
tion, as described below.
DNA extraction and bisulphite modification
Genomic DNA was isolated from tumour tissue using a 
standard phenol-chloroform extraction,23 then bisulphite 
converted using the EZ DNA Methylation Gold Kit (Zymo 
Research, Irvine, CA, USA) as previously described.21,24 
Bisulphite conversion was confirmed by successful polymer-
ase chain reaction with primers specific to bisulphite-con-
verted DNA. To increase the amount and stability of 
bisulphite-converted DNA, whole-genome amplification was 
performed as previously described.21,24
Illumina 450K methylation bead array analyses
Bisulphite-converted DNA from 21 initial presentation blad-
der tumours and 3 normal bladder controls was hybridised to 
Infinium-based HumanMethylation450 BeadChip arrays 
(Illumina, San Diego, CA, USA). Arrays were processed 
according to the manufacturer’s instructions (performed by 
Barts and the London Genome Centre, UK).21,24 Raw array 
data were processed using GenomeStudio software and the 
bioinformatical platform ‘NIMBL’, as we and others have 
described previously.21,24,25 For each probe, methylation was 
reported as a ‘β-value’, where ‘β’ is defined as the ratio of the 
methylated signal intensity over the summed intensity of the 
methylated and unmethylated signals + 100.40 (β values range 
from 0 [unmethylated] to 1 [fully methylated]). NIMBL was 
used to perform ‘peak-based’ correction and to adjust for 
potential differences in array probe-type sensitivity previously 
reported26; all comparative analyses were performed on peak-
based corrected β values, as described previously.21,24 Each 
array passed quality control assessment based on the perfor-
mance of internal controls and the distribution of β values 
across all array CpGs.
As previously described,21,24 we excluded all CpGs for 
which any of the 24 samples displayed: (1) probe detection P 
values of >.05 (unreliable probe data) or (2) missing β values 
(preventing analyses of all samples). We also excluded all CpG 
loci on allosomes (reducing confounding sex-based methyla-
tion differences).
Technical validation of methylation bead chip array 
data
The correlation between ‘450K’ array and Pyrosequencing was 
confirmed across a total of 120 CpGs using Spearman rank 
correlation, as previously reported.21
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Pyrosequencing of sodium bisulphite–converted 
DNA
Pyrosequencing of sodium bisulphite–converted DNA was 
used to validate the discovery cohort array data (21 tumours) 
and to assess methylation in the independent validation tumour 
cohort (32 tumours). A PyroMark Q24 Pyrosequencer, 
PyroMark Q24 Software 2.0, and PyroMark Gold Q24 
Reagents were used, as previously described by us.21,24
Assessment of potential clinical performance
MedCalc Statistical Software (version 17.0.4; Ostend, Belgium; 
https://www.medcalc.org; 2017) was used to perform receiver 
operating characteristics analyses, area under the curve (AUC) 
calculations to determine sensitivity and specificity, and also to 
determine positive and negative predictive values.
STATA (version 8; Stata Corporation, College Station, TX, 
USA) was used to analyse associations between candidate 
methylation biomarkers and clinical or demographic variables. 
In these cases, P < .05 was considered statistically significant.
Results
Technical validation of array by pyrosequencing
As previously reported,21 and after array processing, normalisa-
tion, and peak-based correction, a technical validation con-
firmed a strong positive correlation between array- and 
Pyrosequencing-derived methylation values (Spearman rank 
correlation r = .912, P < .00001; data not shown).
Array f iltering steps
CpGs showing differential methylation between the 
HR-NMIBC no-recurrence tumours and the recurrence and/or 
progression tumours were included where 10 or more of 14 
recurrence/progression tumours showed a ≥0.1 β value differ-
ence relative to all 7 of the no-recurrence tumours. Using these 
criteria, 206 differentially methylated CpGs were identified, as 
represented by heatmap in Figure 1 (cg identifier list of the 206 
CpGs in Supplemental Table S2). In total, 186 were hypermeth-
ylated and 20 were hypomethylated in the recurrence and/or 
progression tumours relative to the no-recurrence tumours.
Figure 1. Heatmap of the 206 differentially methylated CpG sites between the clinical outcomes of HR-NMIBC. Heatmap of the differentially methylated 
CpG sites identified by array analysis. The heatmap separates the 14 recurrence or progression tumours on the left (n = 14) from the no-recurrence 
tumours on the right (n = 7). Each row represents an individual CpG locus, and each column represents a tumour sample (listed beneath the heatmap). 
The colour scale beneath the heatmap represents methylation status: unmethylated is blue (β value = 0.0) and fully methylated is red (β value = 1.0).
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Identif ication of potential prognostic biomarker 
candidates
To focus our assessment on targets with the greatest potential 
for clinical use, the top 20 CpG biomarker candidates (10 
hypermethylated and 10 hypomethylated) were identified on 
the basis of the most frequent differential methylation (in 12 or 
more recurrence/progression tumours of 14) (listed in Table 1 
left-hand panel). These putative biomarker candidates were 
subject to initial screening using MedCalc software (v17.0.4). 
This estimated the potential sensitivity, specificity, and positive 
and negative predictive values for tumour recurrence/progres-
sion of each CpG site in the 21 array tumours (Table 1).
Validation of biomarker potential by pyrosequencing
The 6 best CpG biomarker candidates (cg12228319, 
cg19457237, cg11850659, cg22328426, cg12539415, and 
cg01149192) were identified based on biomarker potential 
(predictive values) suggested in Table 1, and by visual inspec-
tion of plotted array data, where discrimination of tumour/
clinical outcome was most evident based on magnitude of dif-
ferential methylation.
Methylation of these 6 candidates was confirmed by 
Pyrosequencing in the 21 array tumours, which showed good 
concordance with the corresponding array β values (data not 
shown). The 6 candidates were then assessed by Pyrosequencing 
in our independent tumour cohort of 32 HR-NMIBC tumours. 
In total, therefore, 53 tumours were investigated (24 no-recur-
rence and 29 recurrence/progression tumours). These analyses 
confirmed the array-identified patterns of differential methyla-
tion between the clinical outcome sub-types in most of the 
tumours. Based on the greatest discrimination between clinical 
outcome groups shown by these Pyrosequencing data, the top 
2 performing prognostic biomarker candidates were identified 
Table 1. CpG sites showing the greatest differential methylation between the no-recurrence and the recurrence/progression tumours.
CG ID DIRECTION OF 
METHyLATION
RECURRENCE 
AND/OR 
PROGRESSION
SENSITIvITy, % SPECIFICITy, % POSITIvE 
PREDICTIvE 
vALUE, %
NEGATIvE 
PREDICTIvE 
vALUE, %
cg04415176 Hyper 12/14 85.7 100.0 100.0 77.8
cg06391663 Hyper 12/14 85.7 100.0 100.0 77.8
cg19457237 Hyper 12/14 85.7 100.0 100.0 77.8
cg06607594 Hyper 12/14 85.7 100.0 100.0 77.8
cg01392017 Hyper 12/14 85.7 100.0 100.0 77.8
cg13322920 Hyper 12/14 85.7 100.0 100.0 77.8
cg17180705 Hyper 12/14 85.7 100.0 100.0 77.8
cg11850659 Hyper 13/14 92.9 100.0 100.0 87.5
cg12228319 Hyper 13/14 92.9 100.0 100.0 87.5
cg18916488 Hyper 12/14 85.7 100.0 100.0 77.8
cg12539415 Hypo 13/14 92.9 100.0 100.0 87.5
cg12050358 Hypo 12/14 85.7 100.0 100.0 77.8
cg19182537a Hypo 11/14 78.6 100.0 100.0 70.0
cg14729962 Hypo 12/14 85.7 100.0 100.0 77.8
cg04382470 Hypo 12/14 85.7 100.0 100.0 77.8
cg01149192 Hypo 12/14 85.7 100.0 100.0 77.8
cg00397479 Hypo 12/14 85.7 100.0 100.0 77.8
cg03540028 Hypo 12/14 85.7 100.0 100.0 77.8
cg22328426 Hypo 13/14 92.9 100.0 100.0 87.5
cg27084746 Hypo 12/14 85.7 100.0 100.0 77.8
Top 20 sites (with CG identifier) of differential methylation between the clinical outcomes of high-risk non-muscle invasive bladder cancer. The direction of methylation 
change in the recurrence/progression tumours is stated relative to the no-recurrence tumours, with the number of tumours showing differential methylation at each site 
shown. The values for sensitivity, specificity, and positive and negative predictive values of tumour recurrence/progression are given on the right side of the table.
acg19182537 was included with the candidates showing differential methylated 12 or more recurrence/progression tumours of 14, as methylation in one of the recurrence/
progression tumours was very close to the differential methylation threshold used.
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(cg11850659 and cg01149192) (primer sequences: 
Supplemental Table S3).
Again, based on methylation values across all 53 tumours, the 
biomarker potential of cg11850659 and cg01149192 was next 
determined by receiver operating characteristic (ROC) curve 
analyses. As shown in Figure 2, the AUC and the sensitivity and 
specificity values for tumour recurrence and/or progression were 
0.71 (95% confidence interval [CI]: 0.57-0.83), 86.2% and 
54.2% for cg11850659 (methylation values above 51%), and 0.64 
(95% CI 0.50-0.77), 89.7% and 54.2% for cg01149192 (meth-
ylation values equal to or less than 41%) (ROC analyses: 
Supplemental Table S4). The combination of hypermethylation 
of cg11850659 and hypomethylation of cg01149192 was 
assessed using the threshold methylation values above in a 2 × 2 
contingency table. This ‘combination’ biomarker (hypermethyla-
tion of cg11850659 and hypomethylation of cg01149192) 
showed a sensitivity of 82.8%, a specificity of 79.2%, a positive 
predictive value of 82.8%, and a negative predictive value of 
79.2% for HR-NMIBC recurrence and/or progression at/within 
1 year of initial diagnosis. The 10-fold cross-validation with 10% 
of the samples predicted outcome correctly 36 times of 50 (72%).
Biomarker independence from demographic factors 
and treatment duration
To confirm that these 2 DNA methylation biomarker candi-
dates (alone and in combination) were independent predictors 
of disease outcome, potential associations between methylation 
and other known factors were assessed. Multivariate regression 
did not identify any correlations between methylation with 
patient age, sex, or intra-vesical BCG treatment duration 
(Supplemental Table S1). However, data regarding smoking 
history, tumour size, and number, ethnicity, and occupational 
history were not available for these analyses.
Discussion
Similar to other solid organ and haematologic malignancies, 
patterns of DNA methylation correlate with clinical outcomes 
in bladder cancer.14,15 Despite the difficulty in predicting dis-
ease course, HR-NMIBC is rarely investigated as a discrete 
entity for subtype-specific DNA methylation.16,17 We there-
fore used HumanMethylation450 array technology in this 
tumour type to identify potential prognostic biomarkers. After 
the array data were confirmed reliable by technical validation, 
and similar to previous reports,27,28 we used a β value change of 
≥0.1 to identify differential methylation. In this case, we 
grouped the recurrence and progression tumours together for 
assessment relative to the no-recurrence tumours. This group-
ing was considered appropriate as HR-NMIBC tumour recur-
rence or progression may prompt change(s) to the clinical 
management of patients, and both are associated with poorer 
prognosis than no (tumour) recurrence at 1 year.3,5,29 The num-
ber of differentially methylated CpG sites identified was 
broadly in keeping with similar studies in other tumour 
types,28,30 and comparable methylation patterns observed 
between array and independent tumour cohorts for our top 6 
biomarkers suggested that our approach in identifying these 
candidates was robust.
The tumours investigated were initial presentation and 
intra-vesical BCG (treatment) naïve; the associated clinical 
outcomes were recorded prospectively.20 Overall, 45 of 53 
patients received at least 6 intra-vesical instillations of BCG 
(induction) within the first year after tumour resection. As 
such, we reasoned that the methylation patterns identified 
might hold promise as ‘at diagnosis’ predictors of patient/
tumour outcome despite standard treatment, similar to prog-
nostic/treatment-response methylation biomarkers in other 
tumour types.31,32 However, although DNA methylation pat-
terns have been described as sensitive and specific for 
HR-NMIBC diagnosis, methylation has not been previously 
described as reliably predictive of outcome in this tumour type 
when considered separately from low- and intermediate-risk 
NMIBC and/or bladder carcinoma in situ, an aggressive 
tumour type often associated with but histologically and 
molecularly distinct from HR-NMIBC.16–19,33
Figure 2. Receiver operating characteristic (ROC) curves for cg11850659 and cg01149192. ROC curves for the 2 best performing biomarker candidates. 
Hypermethylation of CG11850659 (left) – AUC: 0.71 (95% CI: 0.57-0.83) and hypomethylation of CG01149192 (right) – 0.64 (95% CI: 0.50-0.77). AUC 
indicates area under the curve; CI, confidence interval.
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As described in similar reports,34 our biomarker candidate 
methylation data were used for ROC and AUC analyses to 
estimate sensitivity, specificity, and positive and negative pre-
dictive values for tumour recurrence or progression within 
1 year of initial diagnosis. Hypermethylation of cg11850659 
and hypomethylation of cg01149192 were the best predictors 
of tumour recurrence/progression; however, individually, their 
specificity (54.2%) was considered inadequate for a clinically 
usable test. Hypermethylation of cg11850659 and hypometh-
ylation of cg01149192 in combination, however, demonstrated 
favourable sensitivity, specificity, and positive and negative pre-
dictive values. Furthermore, these values are in keeping with 
those reported in similar studies of, for example, breast and cer-
vical cancers.35,36 Although these data therefore suggest the 
exciting clinical potential of our novel prognostic methylation 
biomarkers in HR-NMIBC, there are no comparable studies 
in this tumour type, and as such, our ability to interpret results 
in the context of previously published data is limited.
Although abnormal methylation at these 2 CpG sites has not 
been previously described as predictive of clinical outcome in any 
tumour type, cg11850659 (chr 6: 164 254 857; open sea) has been 
found hypomethylated in hepatocellular carcinoma,37 whereas 
cg01149192 (chr 5: 180 231 058; lying within an MGAT1 pro-
moter-associated CpG island) has been found hypermethylated 
in head and neck squamous cell carcinoma.38 In this case, hyper-
methylation of cg01149192 was also associated with changes in 
transcript expression; however, methylation as a potential causal 
mechanism of altered gene expression and tumour development 
was not assessed. It is possible therefore that DNA methylation at 
one or more of our identified novel potential biomarker CpG 
sites may be contributory/causal or recurrent/progressive disease, 
rather than just predictive of these outcomes.
Conclusions and Limitations
In summary, we have presented the first 450K array DNA 
methylation assessment of initial presentation and treatment-
naïve HR-NMIBC tumours associated with divergent clinical 
outcomes. Our analyses suggested multiple differentially meth-
ylated CpG sites between recurrence/progression tumours and 
their less aggressive no-recurrence counterparts. Assessment of 
these predictive methylation biomarkers suggests their exciting 
clinical potential to support clinical decision making in this 
unpredictable tumour type.
We recognise that our data represent ‘proof of principle’ and 
that further studies are required to validate our data. Specifically, 
we plan to assess these potential biomarkers in prospective 
studies including larger tumour cohorts, which will also aid 
more reliable assessments of associations with clinical and 
demographic variables than was possible in this study. We also 
recognise that the prevalence of our assessed outcomes (no-
recurrence and recurrence/progression) differs slightly within 
our tumour cohort and therefore we advocate caution in the 
interpretation of the predictive values presented.
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